SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Recall #: D-0388-2026
Affected scope: N/A
Initiated: October 20, 2025

Compiled from official public sources by the publisher. · Updated September 2026

Anthony Trinh, 123Herbals LLC recalled SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shangha… - a critical-severity action.

SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shangha… was recalled by Anthony Trinh, 123Herbals LLC in March 11, 2026. Reason: Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.. Check the official notice for the remedy. Verify recall #D-0388-2026 with the FDA Drug before acting.

The recall

Anthony Trinh, 123Herbals LLC issued this critical-severity FDA Drug recall-Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam..

Critical
severity level: Class I
classification: March 11, 2026
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0388-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China

Reason for recall

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Critical (Class I)
Status	Ongoing
Recall number	D-0388-2026
Date reported	March 11, 2026
Date initiated	October 20, 2025
Recalling firm	Anthony Trinh, 123Herbals LLC
Firm location	Rosemead, CA
Affected scope	N/A
Distribution	USA nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0388-2026) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China. Recalled by Anthony Trinh, 123Herbals LLC. Units affected: N/A.

Why was this product recalled? ▼

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on March 11, 2026. Severity: Critical. Recall number: D-0388-2026.

Where was the recalled product distributed? ▼

Distribution: USA nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Critical), closest by report date among other firms and states.

VOLVO 2025: SEAT BELTS:FRONT:WARNING LIGH… 2026-03-11 VOLKSWAGEN 2025-2026: ELECTRICAL SYSTEM:W… 2026-03-11 Mojo Max Fusion XXX, 500 mg, one capsule … 2026-03-11 MR. 7 SUPER 700000 capsules, 1 capsule bl… 2026-03-11

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

ProRider Recalls Bicycle Helmets Due to R… 2026-03-12 LFTE USA Recalls Playground Swing Set Sea… 2026-03-12 Tomum Minoxidil Hair Serum Spray Bottles … 2026-03-05 HALO Dream Recalls Magic Sleepsuits Due t… 2026-03-05

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported March 11, 2026. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026